[1] ALI A, IJAZ M, KHAN Y R, et al．Role of nanotechnology in animal production and veterinary medicine [J]．Trop Anim Health Prod, 2021, 53(5): 508． 

[2] KAWABATA Y, WADA K, NAKATANI M, et al． Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications [J]．Int J Pharm, 2011, 420(1): 1-10． 

[3] CHEN F, ZHANG Z R, YUAN F, et al．In vitro and in vivo study of N-trimethyl chitosan nanoparticles for oral protein delivery [J]．Int J Pharm, 2008, 349(1/2): 226-233． 

[4] SHAN W, ZHU X, LIU M, et al．Overcoming the diffusion barrier of mucus and absorption barrier of epithelium by selfassembled nanoparticles for oral delivery of insulin [J]． ACS Nano, 2015, 9(3): 2345-2356． 

[5] CONE R A．Barrier properties of mucus [J]．Adv Drug Deliv Rev, 2009, 61(2): 75-85． 

[6] WANG J, KONG M, ZHOU Z, et al．Mechanism of surface charge triggered intestinal epithelial tight junction opening upon chitosan nanoparticles for insulin oral delivery [J]． Carbohydr Polym, 2017, 157: 596-602． 

[7] BOCSIK A, GRÓF I, KISS L, et al．Dual action of the PN159/KLAL/MAP peptide: increase of drug penetration across caco-2 intestinal barrier model by modulation of tight junctions and plasma membrane permeability [J]． Pharmaceutics, 2019, 11(2): 73． 

[8] GEHART H, CLEVERS H．Tales from the crypt: new insights into intestinal stem cells [J]．Nat Rev Gastroenterol Hepatol, 2019, 16(1): 19-34． 

[9] 王秀坤, 李家实．细胞信号转导与中药机理研究[J]．世 界科学技术, 2003, (6): 46-50.

[10] HYUN H, PARK J, WILLIS K, et al．Surface modification of polymer nanoparticles with native albumin for enhancing drug delivery to solidtumors [J]．Biomaterials, 2018, 180: 206-224． 

[11] LIVERSIDGE G G, CONZENTINO P．Drug particle size reduction for decreasing gastric irritancy and enhancing absorption of naproxen in rats [J]．Int J Pharm, 1995, 125(2): 309-313． 

[12] MOU D S, CHEN H B, WAN J L, et al．Potent dried drug nanosuspensions for oral bioavailability enhancement of poorly soluble drugs with pH-dependent solubility [J]．Int J Pharm, 2011, 413(1/2): 237-244． 

[13] AHUJA B K, JENA S K, PAIDI S K, et al．Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension [J]．Int J Pharm, 2015, 478(2): 540-552． 

[14] YI Y N, TU L X, HU K L, et al．The construction of puerarin nanocrystals and its pharmacokinetic and in vivoin vitro correlation(IVIVC) studies on beagle dog [J]． Colloids Surf B Biointerfaces, 2015, 133: 164-170． 

[15] MADHU．Difference between polymer and macromolecule [EB/OL]．(2015-1-21) [2022-03-29]．https://www． differencebetween．com/difference-between-polymer-andvs- macromolecule/． 

[16] YU M R, YANG Y W, ZHU C L, et al．Advances in the transepithelial transport of nanoparticles [J]．Drug Discov Today, 2016, 21(7): 1155-1161． 

[17] BEZRODNYKH E A, ANTONOV Y A, BEREZIN B B, et al．Molecular features of the interaction and antimicrobial activity of chitosan in a solution containing sodium dodecyl sulfate [J]．Carbohydr Polym, 2021, 270: 118352． 

[18] GRENHA A．Chitosan nanoparticles: a survey of preparation methods [J]．J Drug Target, 2012, 20(4): 291- 300． 

[19] SUBBIAH R, RAMALINGAM P, RAMASUNDARAM S, et al．N,N,N-Trimethyl chitosan nanoparticles for controlled intranasal delivery of HBV surface antigen [J]．Carbohydr Polym, 2012, 89(4): 1289-1297． 

[20] ZENG H H, ZHU X, TIAN Q K, et al．In vivo antitumor effects of carboxymethyl chitosan-conjugated triptolide after oral administration [J]．Drug Deliv, 2020, 27(1): 848- 854． 

[21] FAN W W, XIA D N, ZHU Q L, et al．Functional nanoparticles exploit the bile acid pathway to overcome multiple barriers of the intestinal epithelium for oral insulin delivery [J]．Biomaterials, 2018, 151: 13-23． 

[22] SAKLOETSAKUN D, PERERA G, HOMBACH J, et al． The impact of vehicles on the mucoadhesive properties of orally administrated nanoparticles: a case study with chitosan- 4-thiobutylamidine conjugate [J]．AAPS PharmSciTech, 2010, 11(3): 1185-1192． 

[23] A M P O N S A H - E FA H K K , D E M E L E R B , SURYANARAYANAN R．C h a r a c t e r i z i n g d r u g - polymer interactions in aqueous solution with analytical ultracentrifugation [J]．Mol Pharm, 2021, 18(1): 246- 256． 

[24] BABU N J, NANGIA A．Solubility advantage of amorphous drugs and pharmaceutical cocrystals [J]．Crys Growth Des, 2011, 11(7): 2662-2679． 

[25] KOSINSKI A M, BRUGNANO J L, SEAL B L, et al． Synthesis and characterization of a poly(lactic-co-glycolic acid) core + poly(N-isopropylacrylamide) shell nanoparticle system [J]．Biomatter, 2012, 2(4): 195-201． 

[26] TIMMINS P, PYGALL S R, MELIA C D．Hydrophilic matrix tablets for oral controlled release [M]．New York: Springer, 2014． [27] MAŠKOVÁ E, KUBOVÁ K, RAIMI-ABRAHAM B T, et al．Hypromellose-a traditional pharmaceutical excipient with modern applications in oral and oromucosal drug delivery [J]．J Control Release, 2020, 324: 695-727． 

[28] DOLENC A, KRISTL J, BAUMGARTNER S, et al． Advantages of celecoxib nanosuspension formulation and transformation into tablets [J]．Int J Pharm, 2009, 376(1/2): 204-212． 

[29] SEEDHER N, BHATIA S．Solubility enhancement of Cox-2 inhibitors using various solvent systems [J]．AAPS PharmSciTech, 2003, 4(3): E33． 

[30] HOMAYOUNI A, SADEGHI F, VARSHOSAZ J, et al． Comparing various techniques to produce micro/nanoparticles for enhancing the dissolution of celecoxib containing PVP [J]．Eur J Pharm Biopharm, 2014, 88(1): 261-274． 

[31] SHINDE U A, JOSHI P N, JAIN D D, et al．Preparation and evaluation of N-trimethyl chitosan nanoparticles of flurbiprofen for ocular delivery [J]．Curr Eye Res, 2019, 44(5): 575-582． 

[32] RAMALINGAM P, KO Y T．Enhanced oral delivery of curcumin from N-trimethyl chitosan surface-modified solid lipid nanoparticles: pharmacokinetic and brain distribution evaluations [J]．Pharm Res, 2015, 32(2): 389-402．

[33] LIU H L , TU L X, ZHOU Y X, e t a l．Improved bioavailability and antitumor effect of docetaxel by TPGS modified proniosomes: in vitro and in vivo evaluations [J]． Sci Rep, 2017, 7(1): 43372． 

[34] ZHAO J, FENG S S．Effects of PEG tethering chain length of vitamin E TPGS with a Herceptin-functionalized nanoparticle formulation for targeted delivery of anticancer drugs [J]．Biomaterials, 2014, 35(10): 3340-3347． 

[35] LU J Q, HUANG Y X, ZHAO W C, et al．Design and characterization of PEG-derivatized vitamin E as a nanomicellar formulation for delivery of paclitaxel [J]．Mol Pharm, 2013, 10(8): 2880-2890． 

[36] TANAKA K, KANAZAWA T, SHIBATA Y, et al． Development of cell-penetrating peptide-modified MPEGPCL diblock copolymeric nanoparticles for systemic gene delivery [J]．Int J Pharm, 2010, 396(1/2): 229-238． 

[37] PENG W, JIANG X Y, ZHU Y, et al．Oral delivery of capsaicin using MPEG-PCL nanoparticles [J]．Acta Pharmacol Sin, 2015, 36(1): 139-148． 

[38] RAMIREZ J C, HERRERA-ORDONEZ J, GONZALEZ V A．Kinetics of styrene minisuspension polymerization using a mixture PVA-SDS as stabilizer [J]．Polymer, 2006, 47(10): 3336-3343． 

[39] RAMIREZ J C, FLORES-VILLASEOR S E, VARGASREYES E, et al．Preparation of PDLLA and PLGA nanoparticles stabilized with PVA and a PVA-SDS mixture: Studies on particle size, degradation and drug release [J]．J Drug Deliv Sci Tec, 2020, 60: 101907． [40] JAIN A K, GOYAL A K, MISHRA N, et al．PEG-PLAPEG block copolymeric nanoparticles for oral immunization against hepatitis B [J]．Int J Pharm, 2010, 387(1/2): 253- 262． 

[41] JEAN-MICHEL R, PATRICE H, XAVIER B．Assessment of PEG on polymeric particles surface, a key step in drug carrier translation [J]．J Control Release, 2014, 185: 71-87． 

[42] PALACIO J, AGUDELO N A, LOPEZ B L．PLA/Pluronic® nanoparticles as potential oral delivery systems: preparation, colloidal and chemical stability, and loading capacity [J]．J Appl Polym Sci, 2016, 133(33): 43828． 

[43] TOBÍO M, SÁNCHEZ A, VILA A, et al．The role of PEG on the stability in digestive fluids and in vivo fate of PEGPLA nanoparticles following oral administration [J]． Colloids Surf B Biointerfaces, 2000, 18(3/4): 315-323． 

[44] SMART J D．The basics and underlying mechanisms of mucoadhesion [J]．Adv Drug Deliv Rev, 2005, 57(11): 1556-1568． [45] LIU J L, TU L X, CHENG M, et al．Mechanisms for oral absorption enhancement of drugs by nanocrystals [J]．J Drug Deliv Sci Tec, 2020, 56: 101607． 

[46] DANHIER F, ANSORENA E, SILVA J M, et al．PLGAbased nanoparticles: an overview of biomedical applications [J]．J Control Release, 2012, 161(2): 505-522． 

[47] IRANPOUR S, NEJATI V, DELIREZH N, et al． Enhanced stimulation of anti-breast cancer T cells responses by dendritic cells loaded with poly lactic-co-glycolic acid(PLGA) nanoparticle encapsulated tumor antigens [J]． J Exp Clin Cancer Res, 2016, 35(1): 168． 

[48] SILVA-ABREU M, CALPENA A C, ESPINA M, et al． Optimization, biopharmaceutical profile and therapeutic efficacy of pioglitazone-loaded PLGA-PEG nanospheres as a novel strategy for ocular inflammatory disorders [J]．Pharm Res, 2018, 35(1): 11． 

[49] SAKUMA S, SUDO R, SUZUKI N, et al．Behavior of mucoadhesive nanoparticles having hydrophilic polymeric chains in the intestine [J]．J Control Release, 2002, 81(3): 281-290． 

[50] PORNPITCHANARONG C , ROJANARATA T, OPANASOPIT P, et al．Maleimide-functionalized carboxymethyl cellulose: a novel mucoadhesive polymer for transmucosal drug delivery [J]．Carbohydr Polym, 2022, 288: 119368． 

[51] ISHIZU K, YAMASHITA M, ICHIMURA A．Microsphere synthesis by emulsion copolymerization of methyl methacrylate with poly(acrylic acid) macromonomers [J]． Polymer, 1997, 38(21): 5471-5474． 

[52] LEE C F．The effect of aqueous medium contains poly(acrylic acid) on the morphology of composite polymer particle produced by two stages soapless seeded emulsion polymerization [J]．Polymer, 2002, 43(21): 5763-5769． 

[53] CUI F Y, FENG Q , YIN C H．P r epar a t ion and characterization of mucoadhesive polymer-coated nanoparticles [J]．Int J Pharm, 2006, 316(1/2): 154-161． 

[54] LI X P, UEHARA S, SAWANGRAT K, et al．Improvement of intestinal absorption of curcumin by cyclodextrins and the mechanisms underlying absorption enhancement [J]．Int J Pharm, 2018, 535(1/2): 340-349． 

[55] LIU J L, SUN Y B, CHENG M, et al．Improving oral bioavailability of luteolin nanocrystals by surface modification of sodium dodecyl sulfate [J]．AAPS PharmSciTech, 2021, 22(3): 133． 

[56] GAO Y, SUN Y, LIAO G L, et al．DSPE-PEG polymers for improving pulmonary absorption of poorly absorbed macromolecules in rats and relative mechanism [J]．Drug Dev Ind Pharm, 2021, 47(2): 337-346． 

[57] TEKCHANDANI P, KURMI B D, PALIWAL R, et al． Galactosylated TPGS micelles for docetaxel targeting to hepatic carcinoma: development, characterization, and biodistribution study [J]．AAPS PharmSciTech, 2020, 21(5): 174． 

[58] NA Y G, PHAM T M A, BYEON J J, et al．Development and evaluation of TPGS/PVA-based nanosuspension for enhancing dissolution and oral bioavailability of ticagrelor [J]．Int J Pharm, 2020, 581: 119287． 

[59] LIU Y, JIANG Z F, HOU X F, et al．Functional lipid polymeric nanoparticles for oral drug delivery: rapid mucus penetration and improved cell entry and cellular transport [J]．Nanomedicine, 2019, 21: 102075． 

[60] PIETRA M, GALIAZZO G, BRESCIANI F, et al． Evaluation of prognostic factors, including duodenal P-glycoprotein expression, in canine chronic enteropathy [J]．Animals(Basel), 2021, 11(8): 2315． 

[61] ZHU H J , WANG J S, MARKOWITZ J S, e t al． Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana [J]．J Pharmacol Exp Ther, 2006, 317(2): 850-857． 

[62] 张会杰, 熊玉卿．P -糖蛋白药物外排作用的研究进展 [J]．中国临床药理学志, 2004, (4): 317-320． 

[63] WEMPE M F, WRIGHT C, LITTLE J L, et al．Inhibiting efflux with novel non-ionic surfactants: rational design based on vitamin E TPGS [J]．Int J Pharm, 2009, 370(1/2): 93- 102． 

[64] BAEK J S, CHO C W．2-Hydroxypropyl-β-cyclodextrinmodified SLN of paclitaxel for overcoming P-glycoprotein function in multidrug-resistant breast cancer cells [J]．J Pharm Pharm, 2012, 65(1): 72-78． 

[65] VASCONCELOS T, MARQUES S, SARMENTO B．The biopharmaceutical classification system of excipients [J]． Ther Deliv, 2017, 8(2): 65-78． 

[66] RUIZ-PICAZO A, LOZOYA-AGULLO I, GONZÁLEZÁLVAREZ I, et al．Effect of excipients on oral absorption process according to the different gastrointestinal segments [J]．Expert Opin Drug Deliv, 2021, 18(8): 1005-1024． 

[67] YU S W, XU X L, FENG J F, et al．Chitosan and chitosan coating nanoparticles for the treatment of brain disease [J]． Int J Pharm, 2019, 560: 282-293． 

[68] MO Z J, BAN J F, ZHANG Y, et al．Nanostructured lipid carriers-based thermosensitive eye drops for enhanced, sustained delivery of dexamethasone [J]．Nanomedicine, 2018, 13(11): 1239-1253． 

[69] MUNISWAMY V J, RAVAL N, GONDALIYA P, et al． ‘Dendrimer-Cationized-Albumin’ encrusted polymeric nanoparticle improves BBB penetration and anticancer activity of doxorubicin [J]．Int J Pharm, 2019, 555: 77- 99．